Ionis Pharmaceuticals (IONS) Tops Q2 EPS by 1c
Ionis Pharmaceuticals (NASDAQ: IONS) reported Q2 EPS of ($0.57), $0.01 better than the analyst estimate of ($0.58). Revenue for the quarter came in at $126 million versus the consensus estimate of $129.94 million.
GUIDANCE:
Ionis Pharmaceuticals sees FY2021 revenue of $600 million, versus the consensus of $618 million.
For earnings history and earnings-related data on Ionis Pharmaceuticals (IONS) click here.